VanDevender Aaron 4
4 · Applied Molecular Transport Inc. · Filed Dec 28, 2023
Insider Transaction Report
Form 4
VanDevender Aaron
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2023-12-27−15,395→ 0 totalExercise: $47.01Exp: 2031-05-18→ Common Stock (15,395 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-12-27−20,000→ 0 totalExercise: $0.34Exp: 2033-06-14→ Common Stock (20,000 underlying) - Disposition to Issuer
Common Stock
2023-12-27−212,659→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2023-12-27−20,000→ 0 totalExercise: $3.13Exp: 2032-05-24→ Common Stock (20,000 underlying)
Footnotes (3)
- [F1]Pursuant to the Agreement and Plan of Merger dated as of September 21,2023 (the "Merger Agreement") by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. and the Issuer, each share of common stock was tendered in exchange for 0.1331 of a share of Cyclo common stock (the "Transaction Consideration"). Upon consummation of the tender offer, the Reporting Person received Transaction Consideration of 28,305 shares of Cyclo common stock.
- [F2]Pursuant to the the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing.
- [F3]Pursuant to the Merger Agreement, this option was exchanged for an option covering 2,662 shares of Cyclo Common Stock.